Context:
Financial Statements:
| Column 1                                                                                                     | Column 2   | Column 3   | Column 4   | Column 5   | Column 6   | Column 7   | Column 8   | Column 9   | Column 10   | Column 11   | Column 12   |
|:-------------------------------------------------------------------------------------------------------------|:-----------|:-----------|:-----------|:-----------|:-----------|:-----------|:-----------|:-----------|:------------|:------------|:------------|
|                                                                                                              |            |            |            |            |            |            |            |            |             |             |             |
|                                                                                                              | 2020       |            | 2019       |            |            |            |            |            |             |             |             |
| Assets                                                                                                       |            |            |            |            |            |            |            |            |             |             |             |
| Current assets                                                                                               |            |            |            |            |            |            |            |            |             |             |             |
| Cash and cash equivalents (Notes 1 and 2)                                                                    | $          | 13,985     |            |            | 17,305     |            |            |            |             |             |             |
| Marketable securities (Notes 1 and 2)                                                                        | 11,200     |            |            | 1,982      |            |            |            |            |             |             |             |
| Accounts receivable trade, less allowances for doubtful accounts $293(2019, $226)                            | 13,576     |            |            | 14,481     |            |            |            |            |             |             |             |
| Inventories (Notes 1 and 3)                                                                                  | 9,344      |            |            | 9,020      |            |            |            |            |             |             |             |
|                                                                                                              |            |            |            |            |            |            |            |            |             |             |             |
| Prepaid expenses and other receivables                                                                       | 3,132      |            |            | 2,392      |            |            |            |            |             |             |             |
| Assets held for sale (Note 18)                                                                               | —          |            |            | 94         |            |            |            |            |             |             |             |
| Total current assets                                                                                         | 51,237     |            |            | 45,274     |            |            |            |            |             |             |             |
| Property, plant and equipment, net (Notes 1 and 4)                                                           | 18,766     |            |            | 17,658     |            |            |            |            |             |             |             |
| Intangible assets, net (Notes 1 and 5)                                                                       | 53,402     |            |            | 47,643     |            |            |            |            |             |             |             |
| Goodwill (Notes 1 and 5)                                                                                     | 36,393     |            |            | 33,639     |            |            |            |            |             |             |             |
| Deferred taxes on income (Note 8)                                                                            | 8,534      |            |            | 7,819      |            |            |            |            |             |             |             |
| Other assets                                                                                                 | 6,562      |            |            | 5,695      |            |            |            |            |             |             |             |
| Total assets                                                                                                 | $          | 174,894    |            |            | 157,728    |            |            |            |             |             |             |
| Liabilities and Shareholders’ Equity                                                                         |            |            |            |            |            |            |            |            |             |             |             |
| Current liabilities                                                                                          |            |            |            |            |            |            |            |            |             |             |             |
| Loans and notes payable (Note 7)                                                                             | $          | 2,631      |            |            | 1,202      |            |            |            |             |             |             |
| Accounts payable                                                                                             | 9,505      |            |            | 8,544      |            |            |            |            |             |             |             |
| Accrued liabilities                                                                                          | 13,968     |            |            | 9,715      |            |            |            |            |             |             |             |
| Accrued rebates, returns and promotions                                                                      | 11,513     |            |            | 10,883     |            |            |            |            |             |             |             |
| Accrued compensation and employee related obligations                                                        | 3,484      |            |            | 3,354      |            |            |            |            |             |             |             |
| Accrued taxes on income (Note 8)                                                                             | 1,392      |            |            | 2,266      |            |            |            |            |             |             |             |
| Total current liabilities                                                                                    | 42,493     |            |            | 35,964     |            |            |            |            |             |             |             |
| Long-term debt (Note 7)                                                                                      | 32,635     |            |            | 26,494     |            |            |            |            |             |             |             |
| Deferred taxes on income (Note 8)                                                                            | 7,214      |            |            | 5,958      |            |            |            |            |             |             |             |
| Employee related obligations (Notes 9 and 10)                                                                | 10,771     |            |            | 10,663     |            |            |            |            |             |             |             |
| Long-term taxes payable (Note 1)                                                                             | 6,559      |            |            | 7,444      |            |            |            |            |             |             |             |
| Other liabilities                                                                                            | 11,944     |            |            | 11,734     |            |            |            |            |             |             |             |
| Total liabilities                                                                                            | 111,616    |            |            | 98,257     |            |            |            |            |             |             |             |
| Commitments and Contingencies (Note 19)                                                                      |            |            |            |            |            |            |            |            |             |             |             |
| Shareholders’ equity                                                                                         |            |            |            |            |            |            |            |            |             |             |             |
| Preferred stock — without par value (authorized and unissued2,000,000shares)                                 | —          |            |            | —          |            |            |            |            |             |             |             |
| Common stock — par value $1.00per share (Note 12) (authorized4,320,000,000shares; issued3,119,843,000shares) | 3,120      |            |            | 3,120      |            |            |            |            |             |             |             |
| Accumulated other comprehensive income (loss) (Note 13)                                                      | (15,242)   |            |            | (15,891)   |            |            |            |            |             |             |             |
| Retained earnings                                                                                            | 113,890    |            |            | 110,659    |            |            |            |            |             |             |             |
|                                                                                                              | 101,768    |            |            | 97,888     |            |            |            |            |             |             |             |
| Less: common stock held in treasury, at cost (Note 12) (487,331,000shares and487,336,000shares)              | 38,490     |            |            | 38,417     |            |            |            |            |             |             |             |
| Total shareholders’ equity                                                                                   | 63,278     |            |            | 59,471     |            |            |            |            |             |             |             |
| Total liabilities and shareholders’ equity                                                                   | $          | 174,894    |            |            | 157,728    |            |            |            |             |             |             |

---

| Column 1                                                                                  | Column 2   | Column 3   | Column 4   | Column 5   | Column 6   | Column 7   | Column 8   | Column 9   | Column 10   | Column 11   | Column 12   | Column 13   | Column 14   | Column 15   | Column 16   | Column 17   | Column 18   |
|:------------------------------------------------------------------------------------------|:-----------|:-----------|:-----------|:-----------|:-----------|:-----------|:-----------|:-----------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|
|                                                                                           |            |            |            |            |            |            |            |            |             |             |             |             |             |             |             |             |             |
|                                                                                           | 2020       |            | 2019       |            | 2018       |            |            |            |             |             |             |             |             |             |             |             |             |
| Cash flows from operating activities                                                      |            |            |            |            |            |            |            |            |             |             |             |             |             |             |             |             |             |
| Net earnings                                                                              | $          | 14,714     |            |            | 15,119     |            |            | 15,297     |             |             |             |             |             |             |             |             |             |
| Adjustments to reconcile net earnings to cash flows from operating activities:            |            |            |            |            |            |            |            |            |             |             |             |             |             |             |             |             |             |
| Depreciation and amortization of property and intangibles                                 | 7,231      |            |            | 7,009      |            |            | 6,929      |            |             |             |             |             |             |             |             |             |             |
| Stock based compensation                                                                  | 1,005      |            |            | 977        |            |            | 978        |            |             |             |             |             |             |             |             |             |             |
|                                                                                           |            |            |            |            |            |            |            |            |             |             |             |             |             |             |             |             |             |
| Asset write-downs                                                                         | 233        |            |            | 1,096      |            |            | 1,258      |            |             |             |             |             |             |             |             |             |             |
| Contingent consideration reversal                                                         | (1,148)    |            |            | —          |            |            | —          |            |             |             |             |             |             |             |             |             |             |
| Net gain on sale of assets/businesses                                                     | (111)      |            |            | (2,154)    |            |            | (1,217)    |            |             |             |             |             |             |             |             |             |             |
|                                                                                           |            |            |            |            |            |            |            |            |             |             |             |             |             |             |             |             |             |
| Deferred tax provision                                                                    | (1,141)    |            |            | (2,476)    |            |            | (1,016)    |            |             |             |             |             |             |             |             |             |             |
| Credit losses and accounts receivable allowances                                          | 63         |            |            | (20)       |            |            | (31)       |            |             |             |             |             |             |             |             |             |             |
| Changes in assets and liabilities, net of effects from acquisitions and divestitures:     |            |            |            |            |            |            |            |            |             |             |             |             |             |             |             |             |             |
| Decrease/(Increase)  in accounts receivable                                               | 774        |            |            | (289)      |            |            | (1,185)    |            |             |             |             |             |             |             |             |             |             |
| Increase in inventories                                                                   | (265)      |            |            | (277)      |            |            | (644)      |            |             |             |             |             |             |             |             |             |             |
| Increase in accounts payable and accrued liabilities                                      | 5,141      |            |            | 4,060      |            |            | 3,951      |            |             |             |             |             |             |             |             |             |             |
| Increase in other current and non-current assets                                          | (3,704)    |            |            | (1,054)    |            |            | (275)      |            |             |             |             |             |             |             |             |             |             |
| Increase/(Decrease) in other current and non-current liabilities                          | 744        |            |            | 1,425      |            |            | (1,844)    |            |             |             |             |             |             |             |             |             |             |
| Net cash flows from operating activities                                                  | 23,536     |            |            | 23,416     |            |            | 22,201     |            |             |             |             |             |             |             |             |             |             |
| Cash flows from investing activities                                                      |            |            |            |            |            |            |            |            |             |             |             |             |             |             |             |             |             |
| Additions to property, plant and equipment                                                | (3,347)    |            |            | (3,498)    |            |            | (3,670)    |            |             |             |             |             |             |             |             |             |             |
| Proceeds from the disposal of assets/businesses, net                                      | 305        |            |            | 3,265      |            |            | 3,203      |            |             |             |             |             |             |             |             |             |             |
| Acquisitions, net of cash acquired (Note 18)                                              | (7,323)    |            |            | (5,810)    |            |            | (899)      |            |             |             |             |             |             |             |             |             |             |
| Purchases of investments                                                                  | (21,089)   |            |            | (3,920)    |            |            | (5,626)    |            |             |             |             |             |             |             |             |             |             |
| Sales of investments                                                                      | 12,137     |            |            | 3,387      |            |            | 4,289      |            |             |             |             |             |             |             |             |             |             |
| Credit support agreements activity, net                                                   | (987)      |            |            | 338        |            |            | —          |            |             |             |             |             |             |             |             |             |             |
| Other (primarily licenses and milestones)                                                 | (521)      |            |            | 44         |            |            | (464)      |            |             |             |             |             |             |             |             |             |             |
| Net cash used by investing activities                                                     | (20,825)   |            |            | (6,194)    |            |            | (3,167)    |            |             |             |             |             |             |             |             |             |             |
| Cash flows from financing activities                                                      |            |            |            |            |            |            |            |            |             |             |             |             |             |             |             |             |             |
| Dividends to shareholders                                                                 | (10,481)   |            |            | (9,917)    |            |            | (9,494)    |            |             |             |             |             |             |             |             |             |             |
| Repurchase of common stock                                                                | (3,221)    |            |            | (6,746)    |            |            | (5,868)    |            |             |             |             |             |             |             |             |             |             |
| Proceeds from short-term debt                                                             | 3,391      |            |            | 39         |            |            | 80         |            |             |             |             |             |             |             |             |             |             |
| Repayment of short-term debt                                                              | (2,663)    |            |            | (100)      |            |            | (2,479)    |            |             |             |             |             |             |             |             |             |             |
| Proceeds from long-term debt, net of issuance costs                                       | 7,431      |            |            | 3          |            |            | 5          |            |             |             |             |             |             |             |             |             |             |
| Repayment of long-term debt                                                               | (1,064)    |            |            | (2,823)    |            |            | (1,555)    |            |             |             |             |             |             |             |             |             |             |
| Proceeds from the exercise of stock options/employee withholding tax on stock awards, net | 1,114      |            |            | 954        |            |            | 949        |            |             |             |             |             |             |             |             |             |             |
| Credit support agreements activity, net                                                   | (333)      |            |            | 100        |            |            | 25         |            |             |             |             |             |             |             |             |             |             |
| Other                                                                                     | (294)      |            |            | 475        |            |            | (173)      |            |             |             |             |             |             |             |             |             |             |
| Net cash used by financing activities                                                     | (6,120)    |            |            | (18,015)   |            |            | (18,510)   |            |             |             |             |             |             |             |             |             |             |
| Effect of exchange rate changes on cash and cash equivalents                              | 89         |            |            | (9)        |            |            | (241)      |            |             |             |             |             |             |             |             |             |             |
| (Decrease)/Increase in cash and cash equivalents                                          | (3,320)    |            |            | (802)      |            |            | 283        |            |             |             |             |             |             |             |             |             |             |
| Cash and cash equivalents, beginning of year (Note 1)                                     | 17,305     |            |            | 18,107     |            |            | 17,824     |            |             |             |             |             |             |             |             |             |             |
| Cash and cash equivalents, end of year (Note 1)                                           | $          | 13,985     |            |            | 17,305     |            |            | 18,107     |             |             |             |             |             |             |             |             |             |
|                                                                                           |            |            |            |            |            |            |            |            |             |             |             |             |             |             |             |             |             |
| Supplemental cash flow data                                                               |            |            |            |            |            |            |            |            |             |             |             |             |             |             |             |             |             |
| Cash paid during the year for:                                                            |            |            |            |            |            |            |            |            |             |             |             |             |             |             |             |             |             |
| Interest                                                                                  | $          | 904        |            |            | 995        |            |            | 1,049      |             |             |             |             |             |             |             |             |             |
| Interest, net of amount capitalized                                                       | 841        |            |            | 925        |            |            | 963        |            |             |             |             |             |             |             |             |             |             |
| Income taxes                                                                              | 4,619      |            |            | 4,191      |            |            | 4,570      |            |             |             |             |             |             |             |             |             |             |
|                                                                                           |            |            |            |            |            |            |            |            |             |             |             |             |             |             |             |             |             |

---

| Column 1                                              | Column 2   | Column 3   | Column 4   | Column 5   | Column 6   | Column 7   | Column 8   | Column 9   | Column 10   | Column 11   | Column 12   | Column 13   | Column 14   | Column 15   | Column 16   | Column 17   | Column 18   |
|:------------------------------------------------------|:-----------|:-----------|:-----------|:-----------|:-----------|:-----------|:-----------|:-----------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|
|                                                       |            |            |            |            |            |            |            |            |             |             |             |             |             |             |             |             |             |
|                                                       | 2020       |            | 2019       |            | 2018       |            |            |            |             |             |             |             |             |             |             |             |             |
| Sales to customers                                    | $          | 82,584     |            |            | 82,059     |            |            | 81,581     |             |             |             |             |             |             |             |             |             |
| Cost of products sold                                 | 28,427     |            |            | 27,556     |            |            | 27,091     |            |             |             |             |             |             |             |             |             |             |
| Gross profit                                          | 54,157     |            |            | 54,503     |            |            | 54,490     |            |             |             |             |             |             |             |             |             |             |
| Selling, marketing and administrative expenses        | 22,084     |            |            | 22,178     |            |            | 22,540     |            |             |             |             |             |             |             |             |             |             |
| Research and development expense                      | 12,159     |            |            | 11,355     |            |            | 10,775     |            |             |             |             |             |             |             |             |             |             |
| In-process research and development (Note 5)          | 181        |            |            | 890        |            |            | 1,126      |            |             |             |             |             |             |             |             |             |             |
| Interest income                                       | (111)      |            |            | (357)      |            |            | (611)      |            |             |             |             |             |             |             |             |             |             |
| Interest expense, net of portion capitalized (Note 4) | 201        |            |            | 318        |            |            | 1,005      |            |             |             |             |             |             |             |             |             |             |
| Other (income) expense, net                           | 2,899      |            |            | 2,525      |            |            | 1,405      |            |             |             |             |             |             |             |             |             |             |
| Restructuring (Note 20)                               | 247        |            |            | 266        |            |            | 251        |            |             |             |             |             |             |             |             |             |             |
| Earnings before provision for taxes on income         | 16,497     |            |            | 17,328     |            |            | 17,999     |            |             |             |             |             |             |             |             |             |             |
| Provision for taxes on income (Note 8)                | 1,783      |            |            | 2,209      |            |            | 2,702      |            |             |             |             |             |             |             |             |             |             |
| Net earnings                                          | $          | 14,714     |            |            | 15,119     |            |            | 15,297     |             |             |             |             |             |             |             |             |             |
|                                                       |            |            |            |            |            |            |            |            |             |             |             |             |             |             |             |             |             |
| Net earnings per share (Notes 1 and 15)               |            |            |            |            |            |            |            |            |             |             |             |             |             |             |             |             |             |
| Basic                                                 | $          | 5.59       |            |            | 5.72       |            |            | 5.70       |             |             |             |             |             |             |             |             |             |
| Diluted                                               | $          | 5.51       |            |            | 5.63       |            |            | 5.61       |             |             |             |             |             |             |             |             |             |
| Average shares outstanding (Notes 1 and 15)           |            |            |            |            |            |            |            |            |             |             |             |             |             |             |             |             |             |
| Basic                                                 | 2,632.8    |            |            | 2,645.1    |            |            | 2,681.5    |            |             |             |             |             |             |             |             |             |             |
| Diluted                                               | 2,670.7    |            |            | 2,684.3    |            |            | 2,728.7    |            |             |             |             |             |             |             |             |             |             |

---

English News:
The \"Pharmaceutical Treatments for Mental Health Disorders: Global Markets\" report has been added to ResearchAndMarkets.com's offering. This new report on the market for pharmaceutical treatments for mental health disorders provides a brief overview of the pharmaceutical markets, current and future treatments, as well as drug failure/withdrawals and barriers to entry. It examines changes in healthcare regulation and guidance in the development of new agents and reviews activity in mergers and acquisitions that will help to change future treatment paradigms. Report Includes: 46 data tables and 12 additional tables An overview of the global markets for pharmaceutical treatments for mental health disorders Analyses of market trends, with data from 2019, 2020 and projections of compound annual growth rates (CAGRs) through 2025 Evaluation of current market trends, market size, market forecast, pipeline analysis of new products, and regulatory scenarios and detailed analysis of drivers, challenges, and opportunities affecting market growth Description of biological factors such as anatomical, chemical and genetic traits, and psychological reasons such as conflict or trauma on the mental health and discussion on effect of COIVD-19 pandemic, social distancing and social isolation on the mental health conditions A look at the markets for treatment of psychiatric disorders such as depression, anxiety and obsessive-compulsive disorder (OCD) and their co relation with COVID-19 Details of technological advances and improvement in the development of pharmacological treatments, digital therapeutics (DTx) and cognitive behavioural therapy (CBT) Information on tele mental health software such as ReSet, Pears Somryst and Alkili's EndeavorRx which offers personalized treatment strategies and behavioural healthcare platform which plays an important role in the management of mental health disorders Snapshot of leading mental health conditions, and products in phase III development for selected psychiatric disorders Analysis of recent product developments including pharmacological and digital therapeutics, late-stage pipeline products and points of differentiation from existing therapies Market share analysis of the key companies of the industry, their strategic profiling, their competitive landscape and their detailed company profiles including, Eli Lilly, Johnson & Johnson, Pfizer, Takeda, and Shionogi It is estimated that mental health disorders affect one in four adults each year and are the leading cause of impairment and disability across the globe. Mental health disorders refer to a wide range of mental health disorders that affect mood, thinking and behavior. These conditions can occur either due to biological factors such as anatomical, chemical and genetic traits, or psychological reasons such as conflict or trauma. Market research suggests that mental health conditions are likely to rise in the near future due to the consequences of COIVD-19 pandemic, social distancing and social isolation. Reasons for Doing This Study: The treatment of mental health disorders is complex and often involves pharmacological and behavioral interventions. Diagnosis can be challenging, as symptoms can be complicated by comorbid conditions. This report highlights the current diagnosis and treatment of leading mental health disorders and highlights the clinical unmet needs that new formulations, treatment combinations and new mechanisms of action to address or change the future treatment paradigm of these prevalent conditions. There are also several external factors, including changing regulatory guidance and the impact of the COVID-19 pandemic, which may increase access and reimbursement to medication and digital therapeutics to address unmet medical needs. Key Topics Covered: Chapter 1 Introduction Study Goals and Objectives Reasons for Doing This Study Scope of Report Information Sources Methodology Geographic Breakdown Analyst's Credentials Custom Research Related Reports Chapter 2 Summary and Highlights Chapter 3 Depression and Anxiety Market Landscape Segmentation by Drug Class Segmentation by Company Prevalence of Disorders Diagnosis Current Treatments Selective Serotonin Reuptake Inhibitors (SSRIs) Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs) Tricyclic Antidepressants (TCAs) Monoamine Oxidase Inhibitors (MAOIs) Atypical Antipsychotics and Second-Generation Antipsychotics (SGAs) Benzodiazepines Recent Drug Developments Drug/Company Late-Stage Drug Failures/Withdrawals Drugs in Clinical Development to Treat Depression Phase 3 Drugs in Development to Treat Depression Phase 2 Drugs in Development to Treat Depression Drugs in Clinical Development to Treat Anxiety Phase 3 Drugs in Development to Treat Anxiety Phase 2 Drugs in Development to Treat Anxiety Alternative Approaches Digital Therapeutics M&A Activity Future Opportunities Chapter 4 Attention Deficit Hyperactivity Disorder Market Landscape Segmentation by Geography Segmentation by Drug Class Segmentation by Company Prevalence Diagnosis Current Treatments Recent Drug Developments Drugs/Companies Late-Stage Drug Failures/Withdrawals Drugs in Clinical Development to Treat ADHD Phase 3 Drugs in Development to Treat ADHD Phase 2 Drugs in Development to Treat ADHD Alternative Approaches Digital Therapeutics M&A Activity Future Opportunities Chapter 5 Schizophrenia Market Landscape Segmentation by Geography Segmentation by Drug Class Segmentation by Company Prevalence Diagnosis Current Treatments Recent Drug Developments Drugs/Companies Late-Stage Drug Failures/Withdrawals Drugs in Clinical Development to Treat Schizophrenia Phase 3 Drugs in Development to Treat Schizophrenia Phase 2 Drugs in Development to Treat Schizophrenia Alternative Approaches Digital Therapeutics M&A Activity Future Opportunities Chapter 6 Substance Use Disorders Market Landscape Segmentation by Geography Segmentation by Drug Class Segmentation by Company Prevalence Diagnosis Current Treatments Opioid Use Disorders Alcohol Use Disorders Nicotine Use Disorders Recent Drug Developments Drugs in Clinical Development to Substance Abuse Disorder Phase 3 Drugs in Development to Treat Substance Use Disorders Phase 2 Drugs in Development to Treat Substance Use Disorder Alternative Approaches Digital Therapeutics M&A Activity Future Opportunities Chapter 7 Company Profiles Pharmaceutical Companies Abbvie Alkermes Plc Astrazeneca Plc Boehringer Ingelheim International Gmbh Eli Lilly & Co. Glaxosmithkline Plc H Lundbeck A/S Johnson & Johnson Otsuka Holdings Co. Ltd. Pfizer Inc. Shionogi & Co. Ltd. Takeda Pharmaceuticals Co. Ltd. Specialty Pharma And Biotechs Acadia Pharmaceuticals Inc. Adamis Pharmaceuticals Corp. Bioxcel Therapeutics Inc. Intra-Cellular Therapies Inc. Intervexion Therapeutics Ironshore Pharmaceuticals Kempharm Inc. Minerva Neurosciences Inc. Neos Therapeutics Inc. NLS Pharmaceutical Ag Noven Pharmaceuticals Inc. Sage Therapeutics Supernus Pharmaceuticals, Inc. Tonix Pharmaceuticals Holdings Corp. Tris Pharma Inc. Digital Therapeutic Companies Orexo Ab Pear Therapeutics For more information about this report visit https://www.researchandmarkets.com/r/qbmxm9 Media Contact: Research and Markets Laura Wood, Senior Manager [emailprotected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 SOURCE Research and Markets Related Links http://www.researchandmarkets.com

Chinese News:
FDA认为，强生公司的新冠肺炎疫苗虽然有效性低于辉瑞和Moderna，但是仍安全有效。北京时间2月28日早上，美国食品与药品监督管理局(FDA)已批准强生公司旗下杨森制药公司研发的单剂量新冠肺炎疫苗紧急使用授权(EUA)申请，疫苗将用于18岁及以上成人的新冠肺炎预防。这是FDA授权的首个单剂量新冠肺炎疫苗，也是其授权的第三支新冠肺炎疫苗。美国疾病控制与预防中心国家免疫和呼吸系统疾病中心主任Nancy Messonnier表示，强生的新冠肺炎疫苗“在很多情况下令操作更为容易”。“我认为国家卫生部门对这些疫苗的很多考虑更多的是关于强生疫苗的易用性以及可及性。”紧急使用授权(EUA)的条款允许在收集更多数据的同时使用该疫苗。强生计划在2021年下半年向FDA提交生物制品许可申请。美疫苗接种速度或将加快 最近几周，美国卫生官员敦促美国人尽快接种疫苗。官员们越来越担心新出现的病毒变种对抗疫工作产生影响。上周五，美国疾病控制与预防中心主任Rochelle Walensky警告称，随着变异病毒的传播，美国1月初以来报告的新冠肺炎病例数量的下降趋势可能会趋于停滞。FDA表示，基于美国联邦政府的计划，下周将向全国各州、药房和社区健康中心分发近400万剂强生疫苗。密苏里大学堪萨斯分校医学院教授 Jay Portnoy表示，“我们现在就需要推出这种疫苗”。他补充称，“我们很着急”，因为变异的病毒对美国抗击疫情的进展构成了威胁。芝加哥医学院传染病专家Archana Chatterjee表示，强生的疫苗将帮助美国政府“满足当前的需求”，因为各州抱怨辉瑞和Moderna的疫苗供应不足。与辉瑞和Moderna的疫苗不同，强生公司的一剂疫苗方案无需患者再来注射第二剂，而且可以在冰箱温度下保存数月。据强生公司透露，强生公司单剂量新冠肺炎疫苗可采用标准的疫苗储存和分发渠道，方便交付到偏远地区。预计该单剂量疫苗可在-20 C(-4F)的条件下在2年内保持稳定，在2-8 C(36F-46F)常规冷藏条件下最多可在3个月内保持稳定。不过，强生公司也表示，最初的剂量是有限的。强生公司杨森传染病和疫苗子公司美国媒介事务副总裁Richard Nettles于近日对美国众议院议员表示，强生预计到3月底将交付2000万剂疫苗。强生公司已与美国政府达成协议，将在6月底前供应1亿剂强生公司的疫苗。美国政府官员称，他们正在与强生合作，尽快增加供应，将根据CDC免疫接种咨询委员会(ACIP)指南确定优先接种人群。疫苗无特殊安全性问题 此次强生公司的新冠肺炎疫苗是使用一种被称为腺病毒26型(Ad26)的特定病毒生产的。这种疫苗使用Ad26传递一段DNA或遗传物质，用于制造新冠病毒特有的“刺突”蛋白。被改造成疫苗的Ad26不能在人体内复制并引起疾病。在接种这种疫苗后，人的身体会暂时产生“刺突”蛋白，这种蛋白虽不会导致疾病，但会触发免疫系统的防御反应，进而对新冠病毒产生免疫反应。就在疫苗获得紧急授权批准前，强生公司还报告了两例疫苗接种者的严重过敏反应。该公司临床开发和医疗事务主管Macaya Douoguih在周五告诉FDA称，有两人在接种疫苗后不久发生了严重的过敏反应。其中一位来自南非的接种者出现了严重的、危及生命的过敏反应。不过，FDA疫苗和相关生物产品咨询委员会认为，没有发现强生疫苗存在特殊安全性问题。根据FDA周三公布的一份报告，头痛、疲劳和肌肉疼痛是接种疫苗人群中最常见的副作用。FDA官员Peter Marks强调，“经过对数据的彻底分析，FDA的科学家和医生已经确定，该疫苗符合FDA对其安全性和有效性的预期，适合紧急使用。”强生公司于2月4日向FDA提交了其新冠肺炎疫苗的数据。该公司称，FDA的决定基于所获得的所有科学证据，包括来自3期ENSEMBLE研究的数据。临床试验数据显示，强生疫苗单剂接种14天以后，对新冠中症到重症的保护效力为大约67%；28天以后保护效力为66%。此外，这款疫苗接种14天以后对新冠重症的保护效力为大约77%，28天后这一数据为85%。根据公开数据，辉瑞与BioNTech联合研发的新冠肺炎疫苗有效性达到95%，Moderna研发的新冠肺炎疫苗有效性约为94%尽管强生公司的新冠肺炎疫苗有效性数据不及另外两种疫苗，但是传染病专家指出，三种疫苗不能直接通过数字进行对比，因为强生公司的新冠肺炎疫苗是单剂疫苗，而且该公司的临床试验是在有更多感染病例和新的更具传染性病毒变种的情况下进行的。FDA表示，将批准一种安全且至少50%有效的新冠肺炎疫苗。美国疾病控制与预防中心的数据显示，相比之下，接种流感疫苗通常能将人们患流感的风险降低40%至60%。

Japanese News:
ジョンソン・エンド・ジョンソンが第4四半期決算を発表した。売上高は市場予想を上回り、一株あたり利益（EPS）は市場予想を上回る結果となった。 ● 売上高：$22.52B (市場予想：$22.46B、) ● EPS：$2.04 (市場予想：$2.02、) ジョンソン・エンド・ジョンソンの年初来変動率は2%となっており、低調なパフォーマンスで推移している。またジョンソン・エンド・ジョンソンを構成銘柄とするNYダウの年初来変動率は3.48%となっている。 ジョンソン・エンド・ジョンソン以外の医療銘柄決算情報 ユナイテッドヘルスも第4四半期決算を発表している。売上高は市場予想を下回り$100.8B（予想：$101.61B）に、一株あたり利益（EPS）は市場予想を上回る結果の$6.81（予想：$6.74）となった。 またネオゲンの第2四半期決算では、売上高は市場予想を上回り$231.3M（予想：$226.19M）に、一株あたり利益（EPS）は市場予想を上回る結果の$0.11（$-0.01）であった。

Spanish News:
La farmacéutica Johnson & Johnson anunció este martes una estimación de beneficios para el año 2021 que supera las previsiones del mercado, y además aseguró que publicará próximamente los esperados resultados de los ensayos clínicos de su vacuna contra el coronavirus. Anteriormente, la empresa había indicado que revelaría estos resultados para finales de enero. Esto ocurre en un contexto en el que la lucha global contra la pandemia depende en gran medida del suministro suficiente y oportuno de múltiples vacunas. Johnson & Johnson, conocida también por su amplia gama de dispositivos médicos además de su actividad farmacéutica, anticipa para este año una ganancia ajustada de entre 9,40 y 9,60 dólares por acción, cifra superior a la expectativa promedio de los analistas de 8,99 dólares, según datos proporcionados por IBES de Refinitiv. En contraste, las ganancias de la compañía durante el cuarto trimestre del año anterior se redujeron un 56,7%, alcanzando solo 1.740 millones de dólares, debido principalmente a gastos legales de aproximadamente 2.900 millones de dólares relacionados con litigios. Entre estas demandas legales se encuentran casos relacionados con la venta de opioides, complicaciones por sus mallas vaginales y litigios vinculados a su línea de talcos. Por otro lado, las ventas del último trimestre aumentaron hasta alcanzar los 22.480 millones de dólares frente a los 20.750 millones registrados en el mismo periodo del año previo, impulsadas principalmente por la creciente demanda de medicamentos oncológicos.

Greek News:
Η εταιρεία Johnson & Johnson έδωσε ιδιαίτερη έμφαση στην Έρευνα και Ανάπτυξη (R&D), αυξάνοντας το 2020 τις σχετικές δαπάνες κατά 7,1%, στα $ 12,16 δισεκατομμύρια, από $ 11,36 δισεκατομμύρια το 2019. Η άνοδος αυτή ανέβασε το ποσοστό των δαπανών R&D στο 14,7% των συνολικών πωλήσεων, έναντι 13,8% την προηγούμενη χρονιά. Η αύξηση αποδίδεται κυρίως στη μεγαλύτερη συμβολή των πωλήσεων στον φαρμακευτικό τομέα, την εντατικοποίηση των επενδύσεων στον κλάδο των Ιατρικών Συσκευών, ιδιαίτερα στη ρομποτική και σε ψηφιακές πρωτοβουλίες αλλά και στην ανάπτυξη του φαρμακευτικού χαρτοφυλακίου της εταιρείας, με αιχμή το εμβόλιο κατά του COVID-19. Παράλληλα, η Johnson & Johnson συνεχίζει να επενδύει στρατηγικά στην παγκόσμια επέκταση του κλάδου R&D, διαθέτοντας εγκαταστάσεις σε κρίσιμες αγορές όπως οι ΗΠΑ, η Κίνα και η Γερμανία, ενώ παρέχει επιπλέον υποστήριξη σε περισσότερες από 30 χώρες διεθνώς. Η εταιρεία επικεντρώνεται τόσο στην ανάπτυξη νέων καινοτόμων προϊόντων όσο και στη συνεχή βελτίωση της αποτελεσματικότητας και της συμμόρφωσης με τους κανονισμούς, θέτοντας την έρευνα ως βασικό μοχλό βιώσιμης ανάπτυξης και ανταγωνιστικότητας σε ένα διαρκώς μεταβαλλόμενο περιβάλλον.

Question:
What trends can be observed in the company’s revenue amount over the past few years? Please quote the piece(s) of news aligned with the finding(s), if any.

Answer:

Question: What trends can be observed in the company’s revenue amount over the past few years? Please quote the piece(s) of news aligned with the finding(s), if any.

Johnson & Johnson's revenue has shown a positive trend, with yearly sales slightly increased from $82.1B to $82.6B compared to the same quarter in the previous year, reflecting steady growth in demand.

News Evidence: None

Question: How does the company’s balance sheet reflect its financial health in terms of total amount of current assets and the ratio of total liability divided by total equity? Please provide only the final result(s); do not include any calculation steps. Please quote the piece(s) of news aligned with the finding(s), if any.

Johnson & Johnson reported total current assets of $51.2B. The liability-to-equity ratio was approximately 1.76, indicating a high leverage of liabilities compare to equity.

News Evidence:
None

Question: Are there any significant changes or irregularities in the amount of operating, investing and financing cash flow? Please quote the piece(s) of news aligned with the finding(s), if any.

There was a significant improve in negative inancing cash flow, from $18.0B to $6.1B, due to a substantial decrease in stock repurchase and increase of debt issuance. The operating cashflow is stable, but the investing cash outflow increased a lot, due to increased investment purchase. 

News Evidence:
"las ganancias... se redujeron un 56,7%..."

Question: What is the company's R&D ratio (R&D divided by revenue)? Please provide only the final result(s); do not include any calculation steps. Please quote the piece(s) of news aligned with the finding(s), if any.

Johnson & Johnson’s R&D ratio in 2020 was 0.147.

News Evidence:
"το ποσοστό των δαπανών R&D στο 14,7% των συνολικών πωλήσεων"